普伐他汀和微粒化非诺贝特联合应用治疗混合型血脂异常患者的临床效果与安全性  

Study on the Safety of Combined Application of Pravastatin and Micronized Fenofibrate in the Treatment of Patients with Mixed Dyslipidemia

作　　者：姜思羽 姜飞飞 JIANGg Si-Yu;JIANG Fei-Fei(Internal First Department Ward,Panjin City People's Hospital,Panjin 124221,China)

机构地区：[1]盘锦市人民医院内一科病区,辽宁盘锦124221

出　　处：《中国药物经济学》2022年第3期84-87,共4页China Journal of Pharmaceutical Economics

摘　　要：目的探讨混合型血脂异常患者接受普伐他汀和微粒化非诺贝特联合治疗的临床效果与安全性。方法选取2019年1月至2020年9月盘锦市人民医院收治的88例混合型血脂异常患者作为研究对象,按随机数抽样方法分为对照组与试验组,各44例。对照组给予普伐他汀,试验组在对照组基础上加用微粒化非诺贝特治疗,比较两组治疗有效率、血脂指标、血尿素氮(BUN)、肌酐(Cr)、超敏C反应蛋白(hs-CRP)。结果试验组治疗有效率(95.45%)高于对照组(79.55%),差异有统计学意义(P<0.05);治疗前,两组血脂指标和BUN、Cr、hs-CRP比较,差异无统计学意义(P>0.05);治疗后,试验组患者三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)低于对照组,高密度脂蛋白胆固醇(HDL-C)高于对照组,差异有统计学意义(P<0.05);治疗后,试验组患者BUN、Cr高于对照组,hs-CRP低于对照组,差异有统计学意义(P<0.05)。结论混合型血脂异常接受普伐他汀与微粒化非诺贝特联合治疗相比单一普伐他汀治疗效果更好,在改善患者血脂指标、提高治疗有效率方面效果显著,且用药安全性更高。Objective To explore the effect and safety of combined treatment of pravastatin and micronized fenofibrate in patients with mixed dyslipidemia.Methods A total of 88 mixed dyslipidemia patients admitted to Panjin People’s Hospital from January 2019 to September 2020 were selected as the research objects andwere divided into a control groups and an experimental groups according to random number sampling methods,with 44 cases in each group.The control group was given pravastatin,the experimental group was additionally treated with micronized fenofibrate on the basis of the control group,and the treatment efficacy,blood lipid indexes,blood urea nitrogen(BUN),creatinine(Cr),high-sensitivity C-reactive protein were compared between the 2groups(hs-CRP).Results The treatment effective rate(95.45%)of the experimental group was higher than that of the control group(79.55%),and the difference was statistically significant(P<0.05).After treatment,triacylglycerol(TG),total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C)in the experimental group were lower than those in the control group,and high-density lipoprotein cholesterol(HDL-C)were higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the BUN and Cr of the experimental group were higher than those of the control group,and the hs-CRP of the patients was lower than that of the control group,and the difference was statistically significant(P<0.05).Conclusion Combined treatment of mixed dyslipidemia with pravastatin and micronized fenofibrate has better effect than single pravastatin treatment,and it has a significant effect in improving blood lipid indexes and improving treatment efficiency,and the drug is safer.

关 键 词：混合型血脂异常 微粒化非诺贝特 普伐他汀 血脂 不良反应 安全性 

分 类 号：R543.5[医药卫生—心血管疾病] R972[医药卫生—内科学]